Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 5/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 5/20 | 0.56 |
| ▸ | PI4K2A | Q9BTU6 | 5/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.56 |
| ▸ | PIM1 | P11309 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.43 |
| ▸ | XDH | P47989 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7598522 | 0.84 | PIM1 (0.50) | PI4KAPI4K2BPI4K2API4KBPIM1 | |
| Niacinamide SCHEMBL8510810 | 0.81 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBPIM1 | |
| SCHEMBL29711624 | 0.81 | PI4KA (0.59) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL16197989 | 0.74 | XDH (0.77) | XDH | |
| SCHEMBL8920386 | 0.73 | DHFR (0.46) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL8196752 | 0.72 | XDH (0.76) | XDH | |
| SCHEMBL31045570 | 0.72 | ADORA2A (0.44) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL14778071 | 0.72 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBPIM1 | |
| SCHEMBL6380386 | 0.71 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL29400753 | 0.70 | ADORA2A (0.66) | PI4KAPI4K2BPI4K2API4KBADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559763-B2 | FAD2 genes and mutations | CIBUS US LLC (US) | 2026-02-24 | — | — | US | disclosed |
| EP-3772905-B1 | FAD2 GENES AND MUTATIONS | CIBUS US LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4136963-B1 | METHODS AND COMPOSITIONS FOR INCREASING EFFICIENCY OF TARGETED GENE MODIFICATION USING OLIGONUCLEOTIDE-MEDIATED GENE REPAIR | CIBUS US LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12331303-B2 | Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair | CIBUS US LLC (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250066805-A1 | METHODS AND COMPOSITIONS FOR INCREASING EFFICIENCY OF TARGETED GENE MODIFICATION USING OLIGONUCLEOTIDE-MEDIATED GENE REPAIR | CIBUS US LLC (US) | 2025-02-27 | — | — | US | disclosed |
| CN-118830491-A | Shatterproof genes and mutations | 希博斯美国有限公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-118834883-A | Shatterproof genes and mutations | 希博斯美国有限公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20240336931-A1 | SHATTERPROOF GENES AND MUTATIONS | CIBUS US LLC (US) | 2024-10-10 | — | — | US | disclosed |
| CN-111819285-B | Shatterproof genes and mutations | 希博斯美国有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20240263195-A1 | NON-VIRAL DELIVERY OF DNA FOR PROLONGED POLYPEPTIDE EXPRESSION IN VIVO | ARES CAPITAL CORPORATION, AS AGENT | 2024-08-08 | — | — | US | disclosed |
| US-5817786-A | Single-stranded labelled oligonucleotides of preselected sequences | MOLECULAR BIOSYSTEMS, INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5700919-A | Modified phosphoramidite process for the production of modified nucleic acids | BOEHRINGER MANNHIEM GMBH (DE) | 1997-12-23 | — | — | US | disclosed |
| US-5668266-A | Synthesis of single-stranded labelled oligonucleotides of preselected sequence | SYNGENE, INC. (US) | 1997-09-16 | — | — | US | disclosed |
| US-5541313-A | Single-stranded labelled oligonucleotides of preselected sequence | MOLECULAR BIOSYSTEMS, INC. (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0399330-B1 | Modified phosphoramidite process for preparing modified nucleic acids | BOEHRINGER MANNHEIM GMBH (DE) | 1994-12-28 | — | — | EP | disclosed |
| US-4948882-A | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis | SYNGENE, INC. (US) | 1990-08-14 | — | — | US | disclosed |
| EP-0135587-B1 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS | SYNGENE, INC. (US) | 1990-05-02 | — | — | EP | disclosed |
| EP-0135587-A4 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS. | MOLECULAR BIOSYSTEMS INC (US) | 1986-04-02 | — | — | EP | disclosed |
| EP-0135587-A1 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS. | MOLECULAR BIOSYSTEMS INC (US) | 1985-04-03 | — | — | EP | disclosed |
| WO-1984003285-A1 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS | MOLECULAR BIOSYSTEMS INC (US) | 1984-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240263195-A1 | NON-VIRAL DELIVERY OF DNA FOR PROLONGED POLYPEPTIDE EXPRESSION IN VIVO | LNPEP, CD2BP2, VEGFA | PI4KA 3210/4885PI4K2B 3200/4885PI4K2A 2760/4885 |
| US-12559763-B2 | FAD2 genes and mutations | FADS2, FADS1, SCD | PI4KA 1927/4885PI4K2B 875/4885PI4K2A 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.